国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2015年
4期
252-254
,共3页
李明君%李学章%刘桂平%盛延兴
李明君%李學章%劉桂平%盛延興
리명군%리학장%류계평%성연흥
放射疗法,调强适形%食管肿瘤%淋巴转移%卡培他滨
放射療法,調彊適形%食管腫瘤%淋巴轉移%卡培他濱
방사요법,조강괄형%식관종류%림파전이%잡배타빈
Radiotherapy,intensity-modulated%Esophageal neoplasms%Lymphonode metastasis%Capecitabine
目的：观察卡培他滨联合调强放疗治疗食管癌术后纵隔淋巴结转移的近期疗效及不良反应。方法62例食管癌术后纵隔淋巴结转移的患者按随机数字表法随机分为2组，单纯调强放疗组（A 组）31例，卡培他滨联合调强放疗组（B 组）31例。A 组仅采用调强放疗，B 组采用调强放疗联合口服卡培他滨化疗。两组放疗方案、计划相同：总剂量60~66 Gy，（30~33）次/（6~6.5）周，卡培他滨1250 mg/ m2，每日2次，连续14 d，21 d 为1周期，共应用2疗程。治疗期间观察放化疗相关不良反应，放疗结束后1个月复查胸部 CT 评价疗效。结果 A 组：完全缓解（CR）7例，部分缓解（PR）12例，无效（SD）10例，进展（PD）2例，有效率为61.3%（19/31）；B 组：CR 10例，PR 16例，SD 4例，PD 1例，有效率为83.9%（26/31），两组有效率差异有统计学意义（χ2=3.971，P <0.05）。A、B 组的骨髓抑制发生率分别为29.0%、38.7%（χ2=0.648，P =0.421），放射性肺炎发生率分别为19.4%、25.8%（χ2=0.369，P =0.544），差异无统计学意义。结论卡培他滨联合调强放疗治疗食管癌术后纵隔淋巴结转移近期疗效满意，未增加放化疗相关不良反应。
目的：觀察卡培他濱聯閤調彊放療治療食管癌術後縱隔淋巴結轉移的近期療效及不良反應。方法62例食管癌術後縱隔淋巴結轉移的患者按隨機數字錶法隨機分為2組，單純調彊放療組（A 組）31例，卡培他濱聯閤調彊放療組（B 組）31例。A 組僅採用調彊放療，B 組採用調彊放療聯閤口服卡培他濱化療。兩組放療方案、計劃相同：總劑量60~66 Gy，（30~33）次/（6~6.5）週，卡培他濱1250 mg/ m2，每日2次，連續14 d，21 d 為1週期，共應用2療程。治療期間觀察放化療相關不良反應，放療結束後1箇月複查胸部 CT 評價療效。結果 A 組：完全緩解（CR）7例，部分緩解（PR）12例，無效（SD）10例，進展（PD）2例，有效率為61.3%（19/31）；B 組：CR 10例，PR 16例，SD 4例，PD 1例，有效率為83.9%（26/31），兩組有效率差異有統計學意義（χ2=3.971，P <0.05）。A、B 組的骨髓抑製髮生率分彆為29.0%、38.7%（χ2=0.648，P =0.421），放射性肺炎髮生率分彆為19.4%、25.8%（χ2=0.369，P =0.544），差異無統計學意義。結論卡培他濱聯閤調彊放療治療食管癌術後縱隔淋巴結轉移近期療效滿意，未增加放化療相關不良反應。
목적：관찰잡배타빈연합조강방료치료식관암술후종격림파결전이적근기료효급불량반응。방법62례식관암술후종격림파결전이적환자안수궤수자표법수궤분위2조，단순조강방료조（A 조）31례，잡배타빈연합조강방료조（B 조）31례。A 조부채용조강방료，B 조채용조강방료연합구복잡배타빈화료。량조방료방안、계화상동：총제량60~66 Gy，（30~33）차/（6~6.5）주，잡배타빈1250 mg/ m2，매일2차，련속14 d，21 d 위1주기，공응용2료정。치료기간관찰방화료상관불량반응，방료결속후1개월복사흉부 CT 평개료효。결과 A 조：완전완해（CR）7례，부분완해（PR）12례，무효（SD）10례，진전（PD）2례，유효솔위61.3%（19/31）；B 조：CR 10례，PR 16례，SD 4례，PD 1례，유효솔위83.9%（26/31），량조유효솔차이유통계학의의（χ2=3.971，P <0.05）。A、B 조적골수억제발생솔분별위29.0%、38.7%（χ2=0.648，P =0.421），방사성폐염발생솔분별위19.4%、25.8%（χ2=0.369，P =0.544），차이무통계학의의。결론잡배타빈연합조강방료치료식관암술후종격림파결전이근기료효만의，미증가방화료상관불량반응。
Objective To evaluate the efficacy and toxicity of capecitabine combined with intensity modulated radiotherapy( IMRT)for postoperative mediastinal lymph node metastasis in esophageal cancer. Methods A total of 62 esophageal cancer patients with postoperative mediastinal lymph node metastases were randomly divided into the irradiation group(A group,31 cases)and the capecitabine combined with IMRT group( B group,31 cases). Both of two groups received IMRT radiotherapy with a total dose of 60-66 Gy, 30-33 times in 6-6. 5 weeks. The patients in B group were treated with capecitabine(1 250mg/ m2 ,2 f/ d, d1-d14,21 d × 2 cycle). Results Group A:there were 7 cases of complete response(CR),12 of partial response(PR),10 of stable disease(SD),and 2 of progressive disease(PD);the effective rate was 61. 3%(19 / 31). Group B:there were 10 cases of CR,16 of PR,4 of SD,and 1of PD;the effective rate was 83. 9%(26 / 31). There was a statistical significance between the effective rates of A group and B group(χ2 = 3. 971, P < 0. 05). Our experiment showed that the rates of grade Ⅱand Ⅲ myelosuppression in group A and group B were 29. 0% and 38. 7%(χ2 = 0. 648,P = 0. 421). The rates of Ⅰ and Ⅱ level radioactive pneumonia in group A and were 19. 4% and 25. 8%(χ2 = 0. 369,P = 0. 544). The different incidence of the two adverse reactions between group A and B had no statistical significance. Conclusion Compared with IMRT alone,IM-RT combined with capecitabine may have better curative efficacy without increasing toxicity to esophageal cancer patients with postoperative mediastinum lymphonode metastasis.
